Revenue: As of FY2026 Q2, the actual value is USD 9.7 M.

Preliminary Q2 2026 Revenue

SANUWAVE Health, Inc. reported preliminary, unaudited revenues of $9.6 million to $9.8 million for the second quarter ended June 30, 2026, which was above the high end of the company’s revised guidance ranging from $8.5 million to $9.5 million.

Year-over-Year Revenue Comparison

Preliminary second quarter 2026 revenues represent a decrease of approximately 3–5% compared to revenues of $10.1 million in the second quarter of 2025.

Operational Metrics

Sales of consumable applicators achieved all-time records for both unit sales and revenues by significant margins. Capital sales encountered challenges due to stress in the customer base and the presence of a secondary market for used Ultramist systems. SANUWAVE Health, Inc. has implemented a successful program to qualify, train, and support new users acquiring systems through the secondary market, offering trade-in terms for certified pre-owned systems.

Outlook / Guidance

Management anticipates providing a more detailed update when SANUWAVE Health, Inc. reports its Q2 earnings in August. Future operating results and financial condition may be impacted by risks including reductions in CMS reimbursement, financial distress of wound care practices, and the emergence of a secondary market for used Ultramist systems. Additional risks involve the company’s ability to sustain consumable volumes and convert system placements into recurring revenue.